Multiple Myeloma | Specialty

Induction Therapy for Myeloma

January 29th 2020

Emerging Regimens for Smoldering Myeloma

January 29th 2020

Treatment for High-Risk Asymptomatic Myeloma

January 29th 2020

Dr. Bahlis on Daratumumab Plus Lenalidomide and Dexamethasone in Multiple Myeloma

January 29th 2020

Nizar J. Bahlis, MD, discusses daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone in newly diagnosed multiple myeloma.

Dr. Cowan on Efficacy and Safety of BCMA CAR T-Cells in Multiple Myeloma

January 29th 2020

Andrew J. Cowan, MD, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Dr. Shah on Daratumumab-Based Regimens in Frontline Multiple Myeloma

January 28th 2020

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses daratumumab (Darzalex)-based regimens in the frontline treatment of patients with multiple myeloma.

Dr. Martin on Selinexor in Triple-Class Refractory Multiple Myeloma

January 25th 2020

Thomas G. Martin, MD, discusses the use of selinexor in patients with triple-class refractory multiple myeloma.

Updated Data Unveiled With Emerging Treatments in Myeloma

January 23rd 2020

Sandy W. Wong, MD, discusses treatments in the pipeline for multiple myeloma.

Dr. Voorhees on Updated Depth of Response in GRIFFIN Trial in Multiple Myeloma

January 23rd 2020

Peter Voorhees, MD, discusses the updated depth of response data that were reported in the GRIFFIN trial of patients with multiple myeloma.

Frontline Quadruplet Regimens Advance Treatment in Myeloma

January 23rd 2020

Nina Shah, MD, discusses newer treatment options in the frontline and maintenance settings in multiple myeloma. 

Dr. Wong on Antibody-Drug Conjugate Research in Multiple Myeloma

January 23rd 2020

Sandy Wong, MD, discusses the ongoing research of antibody-drug conjugates in multiple myeloma.

Frontline Daratumumab Regimen Approved in EU for Transplant-Eligible Myeloma

January 22nd 2020

The European Commission has granted marketing authorization for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Dr. Anderson on Recent FDA Approvals in Multiple Myeloma

January 22nd 2020

Larry Anderson, MD, PhD, discusses recent FDA approvals in multiple myeloma.

FDA Grants Priority Review to Belantamab Mafodotin for Relapsed/Refractory Myeloma

January 21st 2020

The FDA has granted a priority review designation to a biologics license application for belantamab mafodotin as a treatment for patients with relapsed/refractory multiple myeloma who received prior therapy with an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

Delivering Deep, Durable Remissions Remains Primary Focus in Multiple Myeloma

January 20th 2020

Thomas G. Martin, MD, discusses the current treatment approaches in multiple myeloma, as well as the agents that are generating excitement in relapsed/refractory patient populations.

Dr. Wong on Mitigating Toxicities of Selinexor in R/R Multiple Myeloma

January 18th 2020

Sandy Wong, MD, discusses ways to mitigate the toxicities of selinexor in patients with relapsed/refractory multiple myeloma.

Dr. Munshi on the Antitumor Effect of NKTR-255 in Patients With Myeloma

January 17th 2020

Nikhil C. Munshi, MD, discusses the antitumor effect of NKTR-255 in patients with multiple myeloma.

IMiD-Free Triplet Leads to Prolonged PFS in Relapsed/Refractory Myeloma

January 17th 2020

Saad Z. Usmani, MD, FACP, discusses the results of the CANDOR trial and the impact of these data on clinical practice in multiple myeloma.

Dr. Chaudhry on Novel Treatment Regimens in Relapsed/Refractory Multiple Myeloma

January 16th 2020

Maria Chaudhry, MBBS, a hematologist at The Ohio State University Comprehensive Cancer Center—James, discusses novel treatment regimens in relapsed/refractory multiple myeloma.

Dr. Martin on Treating First Relapse in Multiple Myeloma

January 14th 2020

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco, and co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the management of first relapse in patients with multiple myeloma.